The emergence of the Middle East Respiratory Syndrome coronavirus

Pathogens and Disease

Volumn 71, Issue 2, 2014, Pages 121-136

  Milne Price, Shauna ^a   Miazgowicz, Kerri L ^a   Munster, Vincent J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Coronavirus; Epidemiology; Intervention strategies; MERS CoV; Molecular biology

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID;

ANTIVIRAL THERAPY; CLINICAL FEATURE; CORONAVIRUS; CORONAVIRUS INFECTION; CORTICOSTEROID THERAPY; DEMOGRAPHY; GEOGRAPHIC DISTRIBUTION; HUMAN; INNATE IMMUNITY; INTERMEDIATE HOST; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR BIOLOGY; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RECEPTOR BINDING; REVIEW; VIRAL RESPIRATORY TRACT INFECTION; VIRUS DETECTION; VIRUS TRANSMISSION; ANIMAL; CLASSIFICATION; CORONAVIRUS INFECTIONS; GENETICS; ISOLATION AND PURIFICATION; PATHOLOGY; PHYLOGENY; SURVIVAL; TRANSMISSION; TRAVEL; VIROLOGY; ZOONOSES;

ANIMALS; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR EPIDEMIOLOGY; PHYLOGENY; SURVIVAL ANALYSIS; TRAVEL; ZOONOSES;

EID: 84902811628     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12166     Document Type: Review

References (143)

1. Agnihothram S, Gopal R, Yount B et al. (2013) Platform strategies for rapid response against emerging coronaviruses: MERS-CoV serologic and antigenic relationships in vaccine design. J Infect Dis [Epub ahead of print].
2. Albarrak A, Stephens G, Hewson R & Memish Z (2012) Recovery from severe novel coronavirus infection. Saudi Med J 33: 1265-1269.
3. Al-Daghri N, Al-Attas O, Alokail M, Alkharfy K, Yousef M, Sabico S & Chrousos G (2011) Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic. BMC Med 9: 76.
4. Almazán F, Dediego M, Sola I et al. (2013) Engineering a replication-competent, propagation-defective Middle East Respiratory Syndrome coronavirus as a vaccine candidate. mBio 4: e00650-13.
5. Annan A, Baldwin H, Corman V et al. (2013) Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 19: 456-459.
6. Anthony SJ, Ojeda-Flores R, Rico-Chavez O et al. (2013) Coronaviruses in bats from Mexico. J Gen Virol 94: 1028-1038.
7. Assiri A, Al-Tawfiq J, Al-Rabeeah A et al. (2013a) Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East Respiratory Syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13: 752-761.
8. Assiri A, McGeer A, Perl T et al. (2013b) Hospital outbreak of Middle East Respiratory Syndrome coronavirus. N Engl J Med 369: 407-416.
9. Bermingham A, Chand M, Brown C et al. (2012) Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 17: 20290.
10. Birgit M, Martin M, Patrick CB, Hans WD & Jindrich C (2005) Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 326: 905-908.
11. Brahmbhatt M & Dutta A (2008) On SARS Type Economic Effects During Infectious Disease Outbreaks. The World Bank.
12. Breban R, Riou J & Fontanet A (2013) Interhuman transmissibility of Middle East Respiratory Syndrome coronavirus: estimation of pandemic risk. Lancet 382: 694-699.
13. Buchholz U, Müller M, Nitsche A et al. (2013) Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 18: 20406.
14. Butler D (2013) Tensions linger over discovery of coronavirus. Nat News (online).
15. Cauchemez S, Fraser C, Van Kerkhove M et al. (2013) Middle East Respiratory Syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 14: 50-56.
16. Centers for Disease Control and Prevention C (2013) Updated information on the epidemiology of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection and guidance for the public, clinicians, and public health authorities, 2012-2013. MMWR Morb Mortal Wkly Rep 62: 793-796.
17. Chan K, Peiris J, Lam S, Poon L, Yuen K & Seto W (2011) The effects of temperature and relative humidity on the viability of the SARS coronavirus. Adv Virol 2011: 734690.
18. Chan J, Chan K-H, Kao R et al. (2013a) Broad-spectrum antivirals for the emerging Middle East Respiratory Syndrome coronavirus. J Infect 67: 606-616.
19. Chan J, Chan K-H, Choi G et al. (2013b) Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 207: 1743-1752.
20. Chan R, Chan M, Agnihothram S et al. (2013c) Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 87: 6604-6614.
21. Chen R-C (2006) Treatment of severe acute respiratory syndrome with glucosteroids*. Chest 129: 1441-1452.
22. Chen F, Chan K, Jiang Y et al. (2004) In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31: 69-75.
23. Chen Z, Zhang L, Qin C et al. (2005) Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79: 2678-2688.
24. Chen Y, Rajashankar K, Yang Y et al. (2013) Crystal structure of the receptor-binding domain from newly emerged Middle East Respiratory Syndrome coronavirus. J Virol 87: 10777-10783.
25. Cheng P, Wong D, Tong L et al. (2004) Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 363: 1699-1700.
26. Cheng VC, Chan J, To K & Yuen K (2013) Clinical management and infection control of SARS: lessons learned. Antiviral Res 100: 407-419.
27. Coleman C, Matthews K, Goicochea L & Frieman M (2013) Wild type and innate immune deficient mice are not susceptible to the Middle East Respiratory Syndrome coronavirus. J Gen Virol 95: 408-412.
28. Corman V, Eckerle I, Bleicker T et al. (2012a) Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 17: pii: 20285.
29. Corman V, Müller M, Costabel U et al. (2012b) Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 17: 20334.
30. Cotten M, Lam T, Watson S et al. (2013a) Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 19: 736.
31. Cotten M, Watson S, Kellam P et al. (2013b) Transmission and evolution of the Middle East Respiratory Syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 382: 1993-2002.
32. De Benedictis P, Marciano S, Scaravelli D et al. (2014) Alpha and lineage C betaCoV infections in Italian bats. Virus Genes 48: 366-371.
33. de Groot R (2012) Family - Coronaviridae. Virus Taxonomy (King AMQ, Adams MJ, Carstens EB & Lefkowitz EJ, eds), pp. 806-828. Elsevier, San Diego, CA.
34. de Sousa R, Reusken C & Koopmans M (2013) MERS coronavirus: data gaps for laboratory preparedness. J Clin Virol 59: 4-11.
35. de Wit E, Prescott J, Baseler L et al. (2013a) The Middle East Respiratory Syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE 8: e69127
36. de Wit E, Rasmussen A, Falzarano D et al. (2013b) Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. P Natl Acad Sci USA 110: 16598-16603.
37. Deming D, Sheahan T, Heise M et al. (2006) Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3: e30525/.
38. Diamond M, Zachariah M & Harris E (2002) Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304: 211-221.
39. Dijkman R, Jebbink MF, Koekkoek SM et al. (2013) Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism. J Virol 87: 6081-6090.
40. Drosten C, Günther S, Preiser W et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976.
41. Drosten C, Seilmaier M, Corman V et al. (2013) Clinical features and virological analysis of a case of Middle East Respiratory Syndrome coronavirus infection. Lancet Infect Dis 13: 745-751.
42. Du L, He Y, Zhou Y, Liu S, Zheng B-J & Jiang S (2009) The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 7: 226-236.
43. Du L, Ma C & Jiang S (2013a) Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J Infect 67: 348-350.
44. Du L, Kou Z, Ma C et al. (2013b) A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS ONE 8: e81587.
45. Du L, Zhao G, Kou Z et al. (2013c) Identification of a receptor-binding domain in the s protein of the novel human coronavirus Middle East Respiratory Syndrome coronavirus as an essential target for vaccine development. J Virol 87: 9939-9942.
46. Engel M, Hoffmann T, Wagner L et al. (2003) The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. P Natl Acad Sci USA 100: 5063-5068.
47. Falzarano D, de Wit E, Martellaro C, Callison J, Munster V & Feldmann H (2013a) Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 3: 1686.
48. Falzarano D, de Wit E, Rasmussen A et al. (2013b) Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19: 1313-1317.
49. Fidler D (2008) Influenza virus samples, international law, and global health diplomacy. Emerg Infect Dis 14: 88-94.
50. Field H, Young P, Yob J, Mills J, Hall L & Mackenzie J (2001) The natural history of Hendra and Nipah viruses. Microbes Infect 3: 307-314.
51. Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH & Osterhaus AD (2004) A previously undescribed coronavirus associated with respiratory disease in humans. P Natl Acad Sci USA 101: 6212-6216.
52. García-Sastre A & Biron C (2006) Type 1 interferons and the virus-host relationship: a lesson in détente. Science (New York, NY) 312: 879-882.
53. Gierer S, Bertram S, Kaup F et al. (2013) The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87: 5502-5511.
54. Graham R, Becker M, Eckerle L, Bolles M, Denison M & Baric R (2012) A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18: 1820-1826.
55. Graham RL, Donaldson EF & Baric RS (2013) A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11: 836-848.
56. Guberina H, Witzke O, Timm J, Dittmer U, Müller M, Drosten C & Bonin F (2013) A patient with severe respiratory failure caused by novel human coronavirus. Infection 42: 203-206.
57. Guery B, Poissy J, el Mansouf L et al. (2013) Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 381: 2265-2272.
58. Gulland A (2013a) Two cases of novel coronavirus are confirmed in France. BMJ (Clinical Research ed.) 346: f3114.
59. Gulland A (2013b) Novel coronavirus spreads to Tunisia. BMJ (Clinical Research ed.) 346: f3372.
60. Haagmans BL, Al Dhahiry SHS, Reusken CBEM et al. (2013) Middle East Respiratory Syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 14: 140-145.
61. Hamre D & Procknow J (1966) A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 121: 190-193.
62. Hart B, Dyall J, Postnikova E et al. (2013) Interferon-beta and mycophenolic acid are potent inhibitors of Middle East Respiratory Syndrome coronavirus in cell-based assays. J Gen Virol 95: 571-577.
63. Health Protection Agency UKNCIt (2013) Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 18: 20427.
64. Hemida M, Perera RA, Wang P et al. (2013) Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 18: e20659.
65. Hijawi B, Abdallat M, Sayaydeh A et al. (2013) Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 19(suppl 1): 8.
66. Hiramatsu H, Kyono K, Higashiyama Y et al. (2003) The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed beta-propeller fold. Biochem Biophys Res Commun 302: 849-854.
67. Hui D & Sung J (2004) Treatment of severe acute respiratory syndrome. Chest 126: 670-674.
68. Ithete NL, Stoffberg S, Corman VM et al. (2013) Close relative of human Middle East Respiratory Syndrome coronavirus in bat, South Africa. Emerg Infect Dis 19: 1697-1699.
69. Josset L, Menachery V, Gralinski L et al. (2013) Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 4: 13.
70. Kindler E, Jónsdóttir H, Muth D et al. (2013) Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. mBio 4: 12.
71. Kopecky-Bromberg S, Martínez-Sobrido L, Frieman M, Baric R & Palese P (2007) Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81: 548-557.
72. Kuiken T, Fouchier R, Schutten M et al. (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362: 263-270.
73. Lambeir A-M, Durinx C, Scharpé S & De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40: 209-294.
74. Lau S, Li K, Tsang A et al. (2013) Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East Respiratory Syndrome coronavirus. J Virol 87: 8638-8650.
75. Lelli D, Papetti A, Sabelli C, Rosti E, Moreno A & Boniotti M (2013) Detection of coronaviruses in bats of various species in Italy. Viruses 5: 2679-2689.
76. Leow M (2013) Correlating cell line studies with tissue distribution of DPP4/TMPRSS2 and human biological samples may better define the viral tropism of MERS-CoV. J Infect Dis 208: 1350-1351.
77. Lipsitch M, Cohen T, Cooper B et al. (2003) Transmission dynamics and control of severe acute respiratory syndrome. Science (New York, NY) 300: 1966-1970.
78. Loutfy M, Blatt L, Siminovitch K et al. (2003) Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290: 3222-3228.
79. Lu G, Hu Y, Wang Q et al. (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500: 227-231.
80. Luo S, Li P, Zhang L, Guan Y, Butt K & Wong K (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
81. Mahalingam S, Herrero L, Playford E et al. (2012) Hendra virus: an emerging paramyxovirus in Australia. Lancet Infect Dis 12: 799-807.
82. Mailles A, Blanckaert K, Chaud P et al. (2013) First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 18: e20502.
83. Masters P (2006) The molecular biology of coronaviruses. Adv Virus Res 66: 193-292.
84. McIntosh K, Dees JH, Becker WB, Kapikian AZ & Chanock RM (1967) Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. P Natl Acad Sci USA 57: 933-940.
85. Memish Z, Zumla A & Assiri A (2013a) Middle East Respiratory Syndrome coronavirus infections in health care workers. N Engl J Med 369: 884-886.
86. Memish Z, Zumla A, Al-Hakeem R, Al-Rabeeah A & Stephens G (2013b) Family cluster of Middle East Respiratory Syndrome coronavirus infections. N Engl J Med 368: 2487-2494.
87. Memish Z, Mishra N, Olival K et al. (2013c) Middle East Respiratory Syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 19: e131172.
88. Meyer BMM, Corman VM, Reusken CBEM, Ritz D & Godeke GD (2014) Antibodies against MERS Coronavirus in Dromedary Camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis 20: e131746.
89. Mou H, Raj V, van Kuppeveld F, Rottier P, Haagmans B & Bosch B (2013) The receptor binding domain of the new Middle East Respiratory Syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 87: 9379-9383.
90. Mukasa-Mugerwa E 1981. The Camel (Camelus dromedarius): A Bibliographical Review. International Livestock Research Institute (ILCA), Addis Ababa.
91. Müller M, Raj V, Muth D et al. (2012) Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. mBio 3: e00515.
92. Munster V, de Wit E & Feldmann H (2013) Pneumonia from human coronavirus in a macaque model. N Engl J Med 368: 1560-1562.
93. Nel L (2013) Discrepancies in data reporting for rabies, Africa. Emerg Infect Dis 19: 529-533.
94. Nicholls J, Poon L, Lee K et al. (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361: 1773-1778.
95. Niemeyer D, Zillinger T, Muth D et al. (2013) Middle East Respiratory Syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 87: 12489-12495.
96. Nishiyama A, Wakasugi N, Kirikae T et al. (2008) Risk factors for SARS infection within hospitals in Hanoi, Vietnam. Jpn J Infect Dis 61: 388-390.
97. Ofner-Agostini M, Gravel D, McDonald L et al. (2006) Cluster of cases of severe acute respiratory syndrome among Toronto healthcare workers after implementation of infection control precautions: a case series. Infect Control Hosp Epidemiol 27: 473-478.
98. Ohnuma K, Haagmans B, Hatano R et al. (2013) Inhibition of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection by anti-CD26 monoclonal antibody. J Virol 87: 13892-13899.
99. Omrani A, Matin M, Haddad Q, Al-Nakhli D, Memish Z & Albarrak A (2013) A family cluster of Middle East Respiratory Syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 17: 72.
100. Peiris J, Chu C, Cheng VC et al. (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361: 1767-1772.
101. Penttinen P, Kaasik-Aaslav K, Friaux A et al. (2013) Taking stock of the first 133 MERS coronavirus cases globally - is the epidemic changing?. Euro Surveill 18: e20596.
102. Perera R, Wang P, Gomaa M et al. (2013) Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 18: e20574.
103. Perlman S & Netland J (2009) Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7: 439-450.
104. Puzelli S, Azzi A, Santini M et al. (2013) Investigation of an imported case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013. Euro Surveill 18: e20564.
105. Raj V, Mou H, Smits S et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495: 251-254.
106. Raj VS, Smits SL, Provacia LB et al. (2014) Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4 mediated entry of the Middle East Respiratory Syndrome coronavirus. J Virol 88: 1834-1838.
107. Randall R & Goodbourn S (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
108. Reusken C, Ababneh M, Raj VS et al. (2013a) Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill 18: e20662.
109. Reusken C, Haagmans B, Müller M et al. (2013b) Middle East Respiratory Syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 13: 859-866.
110. SARS Epidemiology Working Group (2003) Consensus Document on the Epidemiology of Severe Acute Respiratory Syndrome. World Health Organization, Geneva.
111. Sawicki S, Sawicki D & Siddell S (2007) A contemporary view of coronavirus transcription. J Virol 81: 20-29.
112. Scobey T, Yount B, Sims A et al. (2013) Reverse genetics with a full-length infectious cDNA of the Middle East Respiratory Syndrome coronavirus. P Natl Acad Sci USA 110: 16157-16162.
113. Sizun J, Yu M & Talbot P (2000) Survival of human coronaviruses 229E and OC43 in suspension and after drying onsurfaces: a possible source ofhospital-acquired infections. J Hosp Infect 46: 55-60.
114. Smith E, Blanc H, Vignuzzi M & Denison M (2013) Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 9: e1003565.
115. Song F, Fux R, Provacia L et al. (2013) Middle East Respiratory Syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 87: 11950-11954.
116. Stockman L, Bellamy R & Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3: e343.
117. Svoboda T, Henry B, Shulman L et al. (2004) Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med 350: 2352-2361.
118. Tan E, Ooi E, Lin C-Y, Tan H, Ling A, Lim B & Stanton L (2004) Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 10: 581-586.
119. Taylor K & Mossman K (2013) Recent advances in understanding viral evasion of type I interferon. Immunology 138: 190-197.
120. Thackray L & Holmes K (2004) Amino acid substitutions and an insertion in the spike glycoprotein extend the host range of the murine coronavirus MHV-A59. Virology 324: 510-524.
121. The WHO MERS-CoV Research Group (2013) State of knowledge and data gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLoS Curr 5, ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
122. Tseng C-T, Sbrana E, Iwata-Yoshikawa N et al. (2012) Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7: e35421.
123. Tusell S, Schittone S & Holmes K (2007) Mutational analysis of aminopeptidase N, a receptor for several group 1 coronaviruses, identifies key determinants of viral host range. J Virol 81: 1261-1273.
124. Twu S-J, Chen T-J, Chen C-J et al. (2003) Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 9: 718-720.
125. van Boheemen S, de Graaf M, Lauber C et al. (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3: e00473-12.
126. van der Hoek L, Pyrc K, Jebbink MF et al. (2004) Identification of a new human coronavirus. Nat Med 10: 368-373.
127. van Doremalen N, Bushmaker T & Munster V (2013) Stability of Middle East Respiratory Syndrome coronavirus (MERS-CoV) under different environmental conditions. Euro Surveill 18: e20590.
128. Villarroel M, Hidalgo M & Jimeno A (2009) Mycophenolate mofetil: an update. Drugs Today (Barc) 45: 521-532.
129. Wacharapluesadee S, Sintunawa C, Kaewpom T et al. (2013) Group C betacoronavirus in bat guano fertilizer, Thailand. Emerg Infect Dis 19: 1349-1351.
130. Wang N, Shi X, Jiang L et al. (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23: 986-993.
131. WHO (2013a) Risk Factors: Tobacco by Country. World Health Organization, Geneva.
132. WHO (2013b) Alert, Response, and Capacity Building Under the International Health Regulations. World Health Organization, Geneva.
133. WHO 2013c. Revised Interim Case Definition for Reporting to WHO - Middle East Respiratory Syndrome Coronavirus (MERS-CoV). World Health Organization Global Alert and Response (GAR) Geneva.
134. WHO (2014) Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Summary and Literature Update. WHO, Global Alert and Response, Geneva.
135. Wilde AHD, Raj VS, Oudshoorn D et al. (2013) MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- treatment. J Gen Virol 94: 1749-1760.
136. Woo P, Lau S, Chu C-M et al. (2005) Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 79: 884-895.
137. Woo PCY, Lau SKP, Li KSM, Tsang AKL & Yuen K-Y (2012) Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerg Microbes Infect 1: e35.
138. Yang Y, Zhang L, Geng H et al. (2013) The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East Respiratory Syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4: 951-961.
139. Yao Y, Bao L, Deng W et al. (2013) An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis 209: 236-242.
140. Zaki A, van Boheemen S, Bestebroer T, Osterhaus A & Fouchier R (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367: 1814-1820.
141. Zhao P, Cao J, Zhao L-J et al. (2005) Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 331: 128-135.
142. Zhou J, Chu H, Li C et al. (2013) Active MERS-CoV replication and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis [Epub ahead of print].
143. Zielecki F, Weber M, Eickmann M et al. (2013) Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol 87: 5300-5304.